



## **Bodisen Hosts Institutional Road Show in China and Sees Record 3rd Quarter Earnings**

Monday October 18, 3:58 pm ET

NEW YORK--(BUSINESS WIRE)--Oct. 18, 2004--Bodisen Biotech, Inc., (stock symbol: BBOI, website: [www.bodisen.com](http://www.bodisen.com)) announced today that U.S. and European institutions and fund managers completed a successful visit to Bodisen in China. During the two day on-site due diligence of Bodisen, institutions and fund managers were joined by the President of Kabani & Co., Bodisen's U.S. GAAP auditing firm. The two day due diligence included meetings and visits with Bodisen's management team, customers, suppliers, product distribution centers, manufacturing facilities, research labs, new manufacturing facilities and local government officials.

The meetings were held to satisfy increasing interest in Bodisen from institutional investors as a result of the company's recent road show in the U.S. and Europe, and included senior executives from New York City-based Westminster Securities, Wall Street firm New York Global Securities through its Beijing office and affiliates, former executives from Societe Generale and Royal Bank of Scotland and London-based investment banking firm Teathers & Greenwood. The institutions and fund managers visiting Bodisen were also joined by the President of Kabani & Co, which is the third largest independent auditing firm in Southern California, representing approximately 50 U.S. public companies.

Commenting on these events, Ms. Qiong Wang, Bodisen's Chairman & CEO stated: "As a leading U.S. company doing business in China serving the rapidly growing organic fertilizer market in China, we are focused on gaining market share and new customers in the \$17 billion per year Chinese fertilizer markets. I always welcome visits from our auditors as well as members of the investment community. With the forthcoming record earnings release for the third quarter 2004 due in the next few weeks, we expect Bodisen to attract even greater attention from institutional investors."

Bodisen Biotech, a Delaware corporation, is a profitable biotech company with proprietary technologies for developing, manufacturing and marketing environmentally friendly organic agricultural products for the Chinese markets.


Using proprietary technologies, Bodisen sells over 60 packaged products, broken down into 3 product categories: Organic Compound Fertilizer; Organic Liquid Fertilizer; and Pesticides & Insecticides. Bodisen's organic fertilizers can be absorbed by plants within 48 hours while enriching soil conditions without the damaging effects associated with chemical fertilizers.

About Bodisen Biotech, Inc.

Bodisen is headquartered in Shaanxi, China, an agricultural hub of China and the economic gateway to the western regions of China. The Bodisen brand is a highly respected organic brand in China. Its "green" products support the mandate of the Chinese national government to increase crop yields for the purpose of decreasing China's dependency on food imports. Bodisen's products enjoy brand recognition and a price premium over competitive brands in China. With distribution in 20 provinces and an expanding geographic footprint, Bodisen is well positioned to take advantage of the growing demand for organic bio agricultural products in China.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.



Bodisen's auditors and fund managers with Bodisen's Managers



Leading investors visit Bodisen's new facility



Karen Wang leading an investor tour of the Bodisen laboratories



Fund manager and US auditor checking product inventory

---

**Contact:**

Bodisen Biotech, Inc.  
Investor Relations:  
Stephen Johnson, 212-566-3503  
[info@bodisen.com](mailto:info@bodisen.com)

---

Source: Bodisen Biotech, Inc.